Cullinan Therapeutics, Inc. (CGEM)
NASDAQ: CGEM · Real-Time Price · USD
12.58
-0.52 (-3.97%)
Nov 20, 2024, 4:00 PM EST - Market closed
Cullinan Therapeutics Employees
Cullinan Therapeutics had 85 employees as of December 31, 2023. The number of employees increased by 23 or 37.10% compared to the previous year.
Employees
85
Change (1Y)
23
Growth (1Y)
37.10%
Revenue / Employee
n/a
Profits / Employee
-$1,688,694
Market Cap
732.50M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 85 | 23 | 37.10% |
Dec 31, 2022 | 62 | 31 | 100.00% |
Dec 31, 2021 | 31 | 7 | 29.17% |
Dec 31, 2020 | 24 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Avanos Medical | 3,771 |
Bioventus | 970 |
Pacira BioSciences | 712 |
Cytek Biosciences | 676 |
Cronos Group | 356 |
Evolus | 273 |
Prothena Corporation | 173 |
CARGO Therapeutics | 116 |
CGEM News
- 7 days ago - Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024 - GlobeNewsWire
- 16 days ago - Cullinan Therapeutics to Participate in Fireside Chat at Stifel 2024 Healthcare Conference - GlobeNewsWire
- 17 days ago - Cullinan Therapeutics to Present Preclinical Data for CLN-978, a CD19-directed T Cell Engager, at ACR Convergence 2024 - GlobeNewsWire
- 5 weeks ago - Cullinan Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for CLN-978 Administered Subcutaneously in Patients with Moderate to Severe Systemic Lupus Erythematosus - GlobeNewsWire
- 2 months ago - Cullinan Therapeutics Receives Approval to Initiate its Global Phase 1 Clinical Trial of CLN-978 for the Treatment of Systemic Lupus Erythematosus - GlobeNewsWire
- 2 months ago - Cullinan Therapeutics Presents Positive Updated Data from Module C of Zipalertinib Pivotal Phase 2b Study at ESMO 2024 - GlobeNewsWire
- 3 months ago - Cullinan Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 6 months ago - Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib - GlobeNewsWire